Your activity: 2 p.v.

Methylcellulose: Pediatric drug information

Methylcellulose: Pediatric drug information
(For additional information see "Methylcellulose: Drug information" and see "Methylcellulose: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Citrucel [OTC];
  • GoodSense Fiber [OTC];
  • Soluble Fiber Therapy [OTC]
Therapeutic Category
  • Laxative
Dosing: Pediatric
Constipation, occasional

Constipation, occasional:

Note: Ensure adequate liquid intake. Use of fiber (either dietary or supplemental) has not shown efficacy in pediatric patients for treatment of constipation, and the NASPGHAN guidelines do not recommend the use of fiber supplements (NASPGHAN [Tabbers 2014]).

Children 6 to <12 years:

Citrucel tablet: Oral: 1 caplet (500 mg fiber); may increase as needed up to 6 doses/day; maximum daily dose: 6 caplets (3,000 mg fiber)/day.

Citrucel powder: Oral: 21/2 level teaspoons (~1,667 mg fiber); may increase dose as needed by 21/2 level teaspoons up to 3 doses/day.

Children ≥12 years and Adolescents:

Citrucel tablet: Oral: 2 caplets (1,000 mg fiber) may increase as needed up to 6 doses/day; maximum daily dose: 12 caplets (6,000 mg fiber)/day.

Citrucel powder: Oral: 1 heaping tablespoon (2,000 mg fiber); may increase dose as needed by 1 heaping tablespoon up to 3 doses/day.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Methylcellulose: Drug information")

Constipation

Constipation: Oral:

Citrucel tablet: Two caplets as needed up to 6 times/day; maximum: 12 caplets/day.

Citrucel powder: 2 g (1 heaping tablespoon) in 8 oz (240 mL) of cold water; increase as needed by 1 heaping tablespoon up to 3 times/day.

Citrucel powder (sugar free): 2 g (1 rounded tablespoon) in 8 oz (240 mL) of cold water; increase as needed by 1 rounded tablespoon up to 3 times/day.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Powder, Oral:

Citrucel: (454 g, 850 g)

Citrucel: (479 g, 907 g, 1191 g) [gluten free, sugar free; orange flavor]

Soluble Fiber Therapy: (454 g)

Tablet, Oral:

Citrucel: 500 mg [contains fd&c yellow #6(sunset yellow)alumin lake]

GoodSense Fiber: 500 mg [contains fd&c yellow #6(sunset yellow)alumin lake]

Generic Equivalent Available: US

May be product dependent

Administration: Pediatric

Oral:

Caplet: Administer each dose with ≥240 mL (8 ounces) of water or other liquid to prevent choking.

Powder: Mix dose with ≥240 mL (8 ounces) of water or other liquid; stir briskly until completely dissolved and drink immediately. Drinking an additional glass of water or other fluids is recommended.

Administration: Adult

Oral: Administer each dose with 8 ounces (240 mL) of water or other liquid to prevent choking.

Storage/Stability

Powder: Store below 25°C (77°F). Protect from humidity.

Tablets: Store at 15°C to 30°C (59°F to 86° F). Protect from moisture.

Use

Relief of occasional constipation (OTC: FDA approved in ages ≥6 years and adults). Note: Although approved for treatment of occasional constipation in pediatric patients and improved bowel movement frequency, current guidelines do not recommend for treatment of functional constipation (NASPGHAN [Tabbers 2014]). Approved ages and uses for generic products may vary; consult labeling for specific information.

Medication Safety Issues
Sound-alike/look-alike issues:

Citrucel may be confused with Citracal

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.

Warnings/Precautions

Dosage form specific issues:

• Phenylalanine: Some products may contain phenylalanine.

Other warnings/precautions:

• Self-medication (OTC use): Prior to self-medication, patients should contact health care provider if they have abdominal pain, nausea, vomiting, or a sudden change in bowel habits lasting 2 weeks. Patients should stop use and call health care provider immediately if rectal bleeding, constipation lasting >7 days, chest pain, vomiting, difficulty breathing or swallowing occurs, or if no bowel movement after use. All doses must be taken with 8 ounces (240 mL) of water to prevent choking; patients who have difficulty swallowing should not use. Do not use for longer than 1 week unless directed by health care provider.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program

Dichlorphenamide: Laxatives may enhance the hypokalemic effect of Dichlorphenamide. Risk C: Monitor therapy

Dietary Considerations

Some products may contain phenylalanine, potassium, and/or sodium.

Pregnancy Considerations

When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald 2003).

Monitoring Parameters

Stool output.

Pricing: US

Tablets (Citrucel Oral)

500 mg (per each): $0.14

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Celevac (GB, IE);
  • Citrucel (BE, LU);
  • Cologel (GB);
  • Dacryolarmes (FR);
  • Davilose (PT);
  • Lacril (BR, DK);
  • Lacrimart (IT);
  • Lacrisyn (CZ);
  • Methylcellulose-Bournonville (LU);
  • Muciplasma (ES);
  • Oftan MC (FI);
  • Tear cell (IN)


For country code abbreviations (show table)
  1. Citrucel (methylcellulose) caplets [prescribing information]. Warren, NJ: GlaxoSmithKline; no date.
  2. Citrucel (methylcellulose) powder [prescribing information]. Moon Township, PA: GlaxoSmithKline; September 2015.
  3. Citrucel (methylcellulose) sugar free powder [prescribing information]. Warren, NJ: GlaxoSmithKline; no date.
  4. Citrucel (methylcellulose) tablet [prescribing information]. Warren, NJ: GlaxoSmithKline; January 2017.
  5. CVS Health Soluble Fiber Therapy (methylcellulose) powder [prescribing information]. Woonsocket, RI: GlaxoSmithKline; September 2016.
  6. Fiber Therapy (methylcellulose) powder [prescribing information]. Livonia, MI: Major Pharmaceuticals; August 2012.
  7. Sunmark Fiber Laxative (methylcellulose) tablet [prescribing information]. San Francisco, CA: McKesson; September 2012.
  8. Tabbers MM, DiLorenzo C, Berger MY, et al; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. doi:10.1097/MPG.0000000000000266 [PubMed 24345831]
  9. Wald A, "Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy," Gastroenterol Clin North Am, 2003, 32(1):309-22. [PubMed 12635420]
Topic 135074 Version 11.0